Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 11/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 10/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 8/20 | 0.43 |
| ▸ | CDC7 | O00311 | 3/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 3/20 | 0.41 |
| ▸ | GABRD | O14764 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845285 | 0.82 | MAPT (0.38) | KMT2ATBK1PIM1PIM3PIM2 | |
| SCHEMBL2763236 | 0.80 | MAOA (0.55) | KMT2AHSD17B10KDM4ESMN1; SMN2 | |
| SCHEMBL2371448 | 0.79 | PIM1 (0.48) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL2763806 | 0.78 | PON1 (0.47) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL29416622 | 0.78 | PIM1 (0.58) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL2588529 | 0.78 | PIM1 (0.58) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL570295 | 0.76 | KMT2A (0.47) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL571197 | 0.76 | KMT2A (0.44) | KMT2ATBK1PIM1CSNK2BCSNK2A2 | |
| SCHEMBL2521053 | 0.76 | TTR (0.59) | KMT2APIM1CSNK2BCSNK2A2PIM3 | |
| SCHEMBL2371190 | 0.75 | GABRP (0.45) | KMT2ATBK1PIM1CSNK2BCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346827-B2 | 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use | AMGEN INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962859-B2 | Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8921363-B2 | Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors | AMGEN INC. (US) | 2014-12-30 | — | — | US | disclosed |
| WO-2012019056-A1 | AMINO-ISO-INDOLE, AMINO-AZA-ISO-INDOLE, AMINO-DIHYDROISOQUINOLINE AND AMINO-BENZOXAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011115938-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS | AMGEN INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| EP-2328903-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010030954-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251190-A1 | SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KMT2A 3694/4885TBK1 2235/4885PIM1 4303/4885 |
| US-20100087429-A1 | SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | BACE1, BACE2, APP | KMT2A 3308/4885TBK1 2162/4885PIM1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.